



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

14 September 2018  
EMA/CAT/568714/2018  
Procedure Management and Committees Support Division

## Committee for Advanced Therapies (CAT) Minutes for the Written Procedure – 15-17 August 2018

Chair: Martina Schübler-Lenz; Vice-Chair: Ilona Reischl

### Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

### Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



## Table of contents

<b>1.</b>	<b>Written Procedure Related Documents</b>	<b>4</b>
1.1.	Agenda (EMA/CAT/553521/2018) for the CAT Written Procedure August 2018 ....	4
<b>2.</b>	<b>Evaluation of ATMPs</b>	<b>4</b>
2.1.	Opinions .....	4
2.2.	Oral explanations .....	4
2.3.	Day 180 List of outstanding issues .....	4
2.4.	Day 120 Lists of questions.....	4
2.5.	Day 80 assessment reports.....	4
2.6.	Ongoing initial full application .....	4
2.7.	New applications .....	4
2.8.	Withdrawal of initial marketing authorisation application .....	4
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation no. 726/2004 .....	4
2.10.	GMP and GCP inspections requests.....	4
2.11.	Type II variations .....	5
2.12.	Other post-authorisation activities .....	5
<b>3.</b>	<b>Certification of ATMPs</b>	<b>5</b>
3.1.	Opinions .....	5
3.2.	Day 60 evaluation reports .....	5
3.3.	Ongoing initial application.....	5
3.4.	New applications .....	5
<b>4.</b>	<b>Scientific Recommendation on Classification of ATMPs</b>	<b>5</b>
4.1.	New requests – appointment of CAT Co-ordinators .....	5
4.1.1.	Genetically modified adeno-associated viral vector serotype 9 (AAV9) expressing short hairpin ribonucleic acid (shRNA) targeting mutant polyadenylate RNA binding protein nuclear 1 (PABPN1) as well as a codon-optimised shRNA-insensitive wildtype PABPN1 - H0005142 .	5
4.1.2.	Organ donor derived haematopoietic stem cells and defined dose of donor-derived immune cells - H0005143 .....	5
4.1.3.	Stromal vascular fraction - H0005151 .....	6
4.2.	Day 30 Co-ordinators’ first reports .....	6
4.3.	Day 60 Co-ordinators’ revised reports following List of Questions .....	6
4.4.	Finalisation of procedures .....	6
4.5.	Follow-ups and guidance .....	6
<b>5.</b>	<b>Scientific Advice</b>	<b>6</b>
5.1.	New requests – appointment of CAT Co-ordinators .....	6
5.2.	CAT Rapporteurs’ reports .....	6

5.3.	List of issues.....	6
5.4.	Finalisation of Scientific Advice procedures.....	6
5.5.	Follow-up of Scientific Advice procedures .....	6
<b>6.</b>	<b>Pre-Authorisation Activities</b>	<b>6</b>
6.1.	Paediatric investigation plans.....	6
6.2.	ITF briefing meetings in the field of ATMPs .....	7
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	7
<b>7.</b>	<b>Organisational, regulatory and methodological matters</b>	<b>7</b>
7.1.	Mandate and organisation of the CAT .....	7
7.2.	Coordination with EMA Scientific Committees.....	7
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups .....	7
7.4.	Co-operation within the EU regulatory network.....	7
7.5.	Co-operation with international regulators.....	7
7.6.	CAT Work Plan.....	7
7.7.	Planning and reporting .....	7
7.8.	Others .....	7
<b>8.</b>	<b>Any other business</b>	<b>8</b>
<b>9.</b>	<b>Explanatory notes</b>	<b>9</b>

## **1. Written Procedure Related Documents**

- 1.1. Agenda (EMA/CAT/553521/2018) for the CAT Written Procedure August 2018**

## **2. Evaluation of ATMPs**

**2.1. Opinions**

No items

**2.2. Oral explanations**

No items

**2.3. Day 180 List of outstanding issues**

No items

**2.4. Day 120 Lists of questions**

No items

**2.5. Day 80 assessment reports**

No items

**2.6. Ongoing initial full application**

No items

**2.7. New applications**

No items

**2.8. Withdrawal of initial marketing authorisation application**

No items

**2.9. Re-examination of initial application procedures under Article 9(2) of Regulation no. 726/2004**

No items

**2.10. GMP and GCP inspections requests**

No items

## 2.11. Type II variations

No items

## 2.12. Other post-authorisation activities

No items

# 3. Certification of ATMPs

## 3.1. Opinions

No items

## 3.2. Day 60 evaluation reports

No items

## 3.3. Ongoing initial application

No items

## 3.4. New applications

No items

# 4. Scientific Recommendation on Classification of ATMPs

## 4.1. New requests – appointment of CAT Co-ordinators

- 4.1.1. Genetically modified adeno-associated viral vector serotype 9 (AAV9) expressing short hairpin ribonucleic acid (shRNA) targeting mutant polyadenylate RNA binding protein nuclear 1 (PABPN1) as well as a codon-optimised shRNA-insensitive wildtype PABPN1 - H0005142
- 

Intended for the treatment of oculopharyngeal muscular dystrophy

Scope: appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

- 4.1.2. Organ donor derived haematopoietic stem cells and defined dose of donor-derived immune cells - H0005143
- 

Intended for the treatment of solid organ transplantation

Scope: adoption of timetable

**Action:** for adoption

#### 4.1.3. Stromal vascular fraction - H0005151

---

Intended for the regeneration of epithelial fibrosis as a result of vulvar lichen sclerosis

Scope: appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

#### 4.2. Day 30 Co-ordinators' first reports

No items

#### 4.3. Day 60 Co-ordinators' revised reports following List of Questions

No items

#### 4.4. Finalisation of procedures

No items

#### 4.5. Follow-ups and guidance

No items

### 5. Scientific Advice

#### 5.1. New requests – appointment of CAT Co-ordinators

#### 5.2. CAT Rapporteurs' reports

No items

#### 5.3. List of issues

No items

#### 5.4. Finalisation of Scientific Advice procedures

No items

#### 5.5. Follow-up of Scientific Advice procedures

No items

### 6. Pre-Authorisation Activities

#### 6.1. Paediatric investigation plans

No items

## **6.2. ITF briefing meetings in the field of ATMPs**

## **6.3. Priority Medicines (PRIME) – Eligibility requests**

No items

### **6.3.1. Month 0 - Start of the procedure**

There are no procedures starting in August. New eligibility requests will appear in the September 2018 agenda.

### **6.3.2. Month 1 – Discussion of eligibility**

### **6.3.3. Month 2 – Recommendation for eligibility**

No items

## **7. Organisational, regulatory and methodological matters**

### **7.1. Mandate and organisation of the CAT**

No items

### **7.2. Coordination with EMA Scientific Committees**

No items

### **7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups**

No items

### **7.4. Co-operation within the EU regulatory network**

No items

### **7.5. Co-operation with international regulators**

No items

### **7.6. CAT Work Plan**

No items

### **7.7. Planning and reporting**

No items

### **7.8. Others**

No items

## **8. Any other business**

No items

Date of next CAT meeting:  
Wednesday 12<sup>th</sup> to Friday 14<sup>th</sup> September 2018



## 9. Explanatory notes

The notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

### Abbreviations / Acronyms

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ICH: International Conference on Harmonisation

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper  
RSI: Request for supplementary information  
SAs: Scientific Advices  
SAG-O: Scientific Advisory Group Oncology  
SAWP: Scientific Advice Working Party  
SR: Summary Report  
SWP: Scientific Working Party  
SME: Small and medium size enterprises  
SmPC: Summary of Products Characteristics  
TT: Timetable


## Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new advanced therapy medicinal products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

### *New applications (sections 2.1. to 2.12.)*

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

### *Oral explanation (section 2.2.)*

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

### *Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)*

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

### *Withdrawal of applications (section 2.7.)*

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

### *New applications (section 2.9.)*

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

### *GMP and GCP Inspections Issues (section 2.10.)*

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

### *Post-authorisation activities (section 2.12.)*

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, quality defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

### **Certification of ATMPs (section 3)**

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

### **Scientific Recommendation on Classification of ATMPs (Section 4)**

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

### **Scientific Advice (section 5)**

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

### **Pre-Authorisation (section 6)**

#### *Paediatric Investigation Plan (PIP)*

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

#### *ITF Briefing meeting in the field of ATMPs*

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

#### *Priority Medicines (PRIME)*

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

#### **Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

#### **Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)